Renaissance Technologies LLC Acquires 412,700 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC

Renaissance Technologies LLC raised its holdings in shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 72.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 979,300 shares of the company’s stock after buying an additional 412,700 shares during the period. Renaissance Technologies LLC’s holdings in Bicycle Therapeutics were worth $4,544,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in BCYC. Armistice Capital LLC boosted its stake in shares of Bicycle Therapeutics by 8.7% during the 4th quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock worth $22,911,000 after acquiring an additional 258,000 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Bicycle Therapeutics during the 4th quarter valued at $954,000. Flax Pond Capital LLC purchased a new stake in shares of Bicycle Therapeutics in the 4th quarter worth $1,229,000. Pinnacle Wealth Management Advisory Group LLC purchased a new stake in shares of Bicycle Therapeutics in the 4th quarter worth $71,000. Finally, Ausdal Financial Partners Inc. purchased a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth $70,000. 86.15% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total value of $25,214.35. Following the completion of the transaction, the chief executive officer directly owned 605,408 shares in the company, valued at $2,585,092.16. This represents a 0.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 9,977 shares of company stock valued at $42,702. Corporate insiders own 22.00% of the company’s stock.

Bicycle Therapeutics Price Performance

NASDAQ:BCYC opened at $3.97 on Friday. The business’s 50-day simple moving average is $4.14 and its two-hundred day simple moving average is $4.84. The stock has a market cap of $277.15 million, a PE ratio of -1.45 and a beta of 1.55. Bicycle Therapeutics PLC Sponsored ADR has a 52 week low of $3.74 and a 52 week high of $9.16.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). The business had revenue of $0.63 million during the quarter, compared to the consensus estimate of $4.22 million. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. Sell-side analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -2.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BCYC. Needham & Company LLC lowered their target price on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th. Wall Street Zen raised Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Citigroup reaffirmed a “market outperform” rating on shares of Bicycle Therapeutics in a research report on Wednesday, June 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $12.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, April 30th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.86.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.